Platelets and Extracorporeal Membrane Oxygenation Veno-venous
France40 participantsStarted 2026-09
Plain-language summary
In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged ≥ 18 years
* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)
* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO
* Equipped with an arterial catheter for blood sampling
* Ability to undergo the 4 blood draws relevant to the study
* Receiving therapeutic anticoagulation with unfractionated heparin
* Enrolled in a social security program or equivalent
* No measures for Limitation and Withdrawal of Therapy have been implemented
Exclusion Criteria:
* Minors
* Patients under court-appointed guardianship or conservatorship
* Pregnant or breastfeeding women
* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia
* Platelet transfusion within 7 days prior to enrollment
* Indication for immediate emergency ECMO preventing blood sampling before placement
* Post-cardiotomy
* Patient on antiplatelet therapy
* Severe thrombocytopenia \<50 G/L
* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Platelet aggregation response over time during venovenous ECMO at baseline
Timeframe: T0: Baseline (before ECMO initiation)
2
Platelet aggregation response over time during venovenous ECMO at Day 2 of ECMO
Timeframe: T1: Day 2 of ECMO
3
Platelet aggregation response over time during venovenous ECMO at Day 5 of ECMO
Timeframe: T2: Day 5 of ECMO
4
Platelet aggregation response over time during venovenous ECMO at Day 8 of ECMO